NYR
Delivery · High$119M23mo
Nyrada
Biotechnology · Cardiovascular / Neurology
Developing Xolatryp for STEMI reperfusion injury (Phase 2) and NYR-BI03 for brain injury (Phase 1 completed). Dual cardiovascular + neuroprotection pipeline.
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.7M
Mar 2026 4C
Runway
23moSTABLE
Based on Mar 2026 4C
Market Cap
$119M
Burn Rate
$0.9M/qtr
Mar 2026 4C
Shares Outstanding
245M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther19 May 2026
Pause in Trading
Trading in NYR securities has been temporarily paused pending a further announcement. The pause indicates an imminent material disclosure or corporate action requiring market suspension.
3M Price
NYR.ASX$0.490-10.9% 3M
Low $0.450High $0.650
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
2 transactionsLast 90dNo Activity
Buys0-1 vs prior
Sells0
$540,0002026-03-09
Catalysts (8)· 3 upcoming · 5 past
Expectedarrow_upwardHigh30 Apr 2026
NYR-BI03 Phase 1 brain injury final results
UpcomingExpectedremoveMed30 June 2026
Xolatryp Phase 2a primary completion (Day 30 safety)
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High75/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High73/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 3 of 3 guided dates· rolling 2yr· of 8 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
·
First Site Activated in Nyradas PROTECT-MI Phase IIa Trial — Delivered on time
·
Xolatryp USPTO — Nyrada Receives Notice of Allowance for Xolatryp US Patent — Delivered on time
·
Pause in Trading — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (3/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓First Site Activated in Nyradas PROTECT-MI Phase IIa Trial· readout — subject to clinical uncertainty— This announcement reports the activation of the first clinical trial site (Nepean Hospital, NSW) for the PROTECT-MI Phase IIa trial, marking the formal launch of recruitment operations. No efficacy or outcome results are available as the trial has only just begun enrolling patients. The prior Phase I trial (48 participants) met its primary endpoint, confirming Xolatryp was safe and well-tolerated at all doses tested.
On time
✓Xolatryp USPTO — Nyrada Receives Notice of Allowance for Xolatryp US Patent— Nyrada received a Notice of Allowance from the United States Patent and Trademark Office for a composition of matter patent covering Xolatryp's chemical structure. The granted patent will provide 20-year IP protection within the United States against unauthorised manufacture, use, sale, or import of Xolatryp.
On time
✓Pause in Trading— Trading in NYR securities has been temporarily paused pending a further announcement. The pause indicates an imminent material disclosure or corporate action requiring market suspension.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2Recruiting
XolatrypPlacebo
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction · Reperfusion Injury · AMI +1 more
RandomizedQuadruple Blind40 Years – 75 Years
Primary endpoint Incidence of Adverse Events
ENROL300
no manual snapshots — enter via record_enrollment.py